



ASX ANNOUNCEMENT

20 January 2026

Non-Executive Director Appointment – Dr. Jeannette Joughin

Key Highlights

- Dr Jeannette (Jeannie) Joughin has been appointed as an Independent, Non-Executive Director to the Board of Directors of Vitrafy Life Sciences Limited.
- Over three decades experience across biotechnology, life sciences and medical technology in United States and Australia with active involvement in venture capital funding and operational support of life science portfolio companies.
- Senior executive and board experience spanning companies ranging in size from start-up to global conglomerates.
- PhD in Immunology underpinning broad commercialisation, operational leadership and subject matter expertise in Vitrafy's prioritised application areas – blood and blood products, and cell and gene therapies.

Overview

Vitrafy Life Sciences Limited (ASX: **VFY**) ("**Vitrafy**" or "**the Company**") is pleased to announce that it has appointed Dr. Jeannie Joughin to its Board of Directors. As a result of the board renewal process announced in October 2025 aimed at supporting the Company's commercial, scientific and market expertise, Dr. Joughin's appointment further strengthens Vitrafy's team on the pathway to improve cryopreservation technology globally.

On her appointment, Dr. Joughin commented: *"I am passionate about seeing Australian innovations improve lives globally, so joining Vitrafy's Board to advance its mission of enhancing patient care through differentiated cryopreservation technology is an incredible opportunity. While cell, gene, and blood therapies have advanced rapidly, cryopreservation remains largely unchanged which makes this global opportunity especially exciting."*

Chair of Vitrafy, Dr. Leigh Farrell extended a warm welcome to Dr. Joughin: *"On behalf of the Board of Vitrafy, I would like to extend a warm welcome to Jeannie. Her extensive expertise in cell and gene and blood related therapies, coupled with a proven track record in scaling innovative technologies, will be invaluable as we pursue our mission to transform patient care through advanced cryopreservation and accelerate Vitrafy's commercialisation journey in the United States."*

Dr Joughin's appointment as an Independent, Non-Executive Director is effective as of 20 January 2026.

Background of Dr. Joughin

With more than three decades of executive and board experience, Dr. Joughin brings deep expertise to Vitrafy, particularly in blood and blood-related application areas. Dr. Joughin has held senior roles at leading organisations including CSL, Bristol Myers Squibb and Enable Injections.



Importantly, Dr. Joughin developed deep strategic insights and in-market expertise in the United States relating to the blood and blood product market whilst working for CSL Behring - the largest of the CSL Limited businesses. The expertise relating to the US blood market will be highly valuable for Vitrafy's commercialisation plans in 2026.

Since transitioning to venture capital in 2021, Dr. Joughin has held various director roles across biotechnology and medical devices in Australia and internationally, supporting portfolio and ASX-listed companies through growth, operations, licensing and business development. She currently serves as a Non-Executive Director of ImmVirX Ltd, Immuron Ltd (IMC.ASX), Argenica Therapeutics (AGN.ASX) and BiVACOR Australia Pty Ltd. She is also a Venture Partner supporting the Healthcare team at OneVentures, one of Australia's leading venture capital firms.

Jeannie holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University and a Diploma of Marketing from the Melbourne Business School.

What's Next at Vitrafy

Further information regarding the release of the first-half results and associated investor briefing will be released alongside the quarter 2, FY2026 Quarterly Activities Report and Appendix 4C which is expected to be released approximately on 29 January 2026.

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Simon Martin

Chief Financial Officer

investors@vitrafy.com

About Vitrafy Life Sciences Limited

Vitrafy Life Sciences Limited (ASX: VFY) has developed breakthrough cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain™ software platform, and Smart Packaging systems.

For more information visit [vitrafy.com](https://www.vitrafy.com).